🇺🇸

US SEC Filing Intelligence

· daily

Biotech Small-Cap Approvals — March 25, 2026

Four neutral FDA approvals occurred in biotech small-caps from March 19-20, 2026: one original NDA for atomoxetine hydrochloride (MAP77 LLC) and three ANDAs for lidocaine hydrochloride (QUAGEN, VIWIT PHARM) and ephedrine sulfate (FRESENIUS KABI USA), all under standard review with no special designations or indications specified. A key pattern is duplication in lidocaine generics (2/3 ANDAs), signaling supply buildup in mature anesthetic markets. No high-impact innovation; routine events imply modest portfolio gains for sponsors amid commoditization risks.

4 total filings
· daily

New Drug Approvals (Original) — March 25, 2026

FDA approvals from March 19-20 (reported March 25) consist of four neutral original approvals under standard review, with no priority, breakthrough, or other designations—three ANDAs (75%) signaling routine generic entries and one NDA. A concentration of two lidocaine hydrochloride ANDAs (QUAGEN, VIWIT PHARM) on consecutive days highlights potential supply increase and competition in this molecule. Overall, low materiality for portfolios; generics-focused sponsors gain minor portfolio depth amid commoditized markets.

4 total filings
· daily

HHS & Healthcare Contracts Intelligence — March 25, 2026

HHS demonstrates sustained commitment to biodefense and vaccine R&D with $530M obligated across two long-term contracts: Emergent BioSolutions' $422M VIGIV deal (potential $706M ceiling) provides high revenue visibility through 2027-2029. Mount Sinai's $108M influenza research award (potential $151M) supports innovation but caps upside via cost-no-fee terms. Cross-cutting theme of unexercised options (~$328M combined) signals potential upside amid execution risks from extended timelines.

2 total filings
· daily

New Federal Contractors — March 25, 2026

This one-day snapshot of new federal contractor data is dominated by a $2.95B NASA/Caltech JPL contract (68% of total value), signaling sustained but neutral space R&D funding with limited equity upside due to nonprofit status. Four bullish signals highlight $1.13B in HHS health/pharma/IT and DHS/GSA security/IT contracts, offering reliable multi-year revenue to for-profits like Elevance Health, Emergent BioSolutions, Elbit Systems, and Pyramid Systems. Long-duration commitments (avg. end 2027+) provide visibility but concentrate risks in execution and subawards amid $1.3B unoutlayed.

7 total filings
· daily

Significant Contract Modifications ($10M+) — March 25, 2026

HHS dominates with $1.19B across four contracts (28% of total), signaling sustained federal health IT, biopharma, and R&D spending through 2027+. NASA's $2.95B Caltech JPL modification anchors 68% of volume but offers neutral equity impact as a nonprofit. Bullish signals in for-profit IT/services (Elevance, Emergent, ElbitAmerica, Pyramid) highlight $1.13B in reliable revenue ramps, with minimal outlays in newer awards indicating near-term cash flow acceleration.

7 total filings
· daily

Contract Deobligations Alert — March 25, 2026

Deobligations alert reveals $4.34B in major contract obligations dominated by NASA's $2.95B Caltech/JPL award (68% of total), signaling stable space R&D funding through 2028 but neutral equity impact as nonprofit. Four bullish signals ($1.13B total) highlight reliable revenue for Elevance Health, Emergent BioSolutions, ElbitAmerica, and Pyramid Systems in health IT/pharma, surveillance, and HUD IT through 2026-2030. HHS contracts aggregate ~$1.19B with long-term outlays, underscoring healthcare services resilience amid execution risks from firm-fixed pricing and subawards.

7 total filings
· daily

Contract Option Exercises — March 25, 2026

A $4.34B batch of contract option exercises is dominated by a single $2.95B NASA award to Caltech (68% of total), signaling sustained U.S. space R&D funding through 2028 but limited equity upside due to nonprofit status. Four bullish signals ($1.23B total) highlight reliable revenue for for-profit firms in health IT/pharma (Elevance, Emergent) and security/IT (ElbitAmerica, Pyramid), with performance extending to 2030. Long-term visibility tempers execution risks from firm-fixed-price structures and zero-outlay awards, prioritizing HHS/DHS exposure over neutral nonprofits.

7 total filings
· daily

NASA & Space Contracts Intelligence — March 25, 2026

NASA's $2.95B contract with Caltech for JPL operations signals sustained commitment to space R&D through 2028, with $2.43B already outlayed and $3.15B potential including options. Direct equity impacts are limited due to Caltech's nonprofit status, but underscores stability in NASA's FFRDC model for missions like Europa Clipper. Investors should monitor task order execution amid funding variability risks.

1 total filings
· daily

All HHS Contracts — March 25, 2026

HHS awarded $1.19B across 4 contracts in this period, with 68% ($928M) to for-profits signaling reliable multi-year revenue in IT services and biopharma stockpiling through 2027+. Bullish signals dominate for Elevance Health and Emergent BioSolutions due to high outlays (avg 55% obligated) and option upside to $858M total ceiling. Neutrals for nonprofits highlight steady R&D funding but cap investor upside amid subaward dependencies and execution risks to 2027.

4 total filings
· daily

Mega Contracts Monitor ($100M+) — March 25, 2026

HHS dominates with $1.19B across four contracts in IT services, biodefense pharma, and R&D support, signaling sustained federal health spending through 2027+. NASA's $2.95B JPL renewal underscores stable space R&D funding but limited equity upside due to nonprofit recipient. Bullish signals on for-profit contractors (Elevance Health, Emergent BioSolutions, ElbitAmerica) highlight reliable multi-year revenue amid neutral nonprofit exposures.

6 total filings
· daily

High-Value Federal Grants ($5M+) — March 25, 2026

A $4.34B batch dominated by a single $2.95B NASA/Caltech JPL contract (68% of total) underscores stable space R&D funding through 2028, but limited equity upside due to nonprofit status. Four bullish signals ($1.13B total) highlight revenue visibility in HHS IT/pharma and DHS/GSA security/IT via for-profits like Elevance Health, Emergent BioSolutions, ElbitAmerica, and Pyramid Systems, with contracts extending to 2030. Neutrals ($3.21B, mostly nonprofits) signal lower-risk but non-investable flows in health R&D; watch outlay execution lags ($0 outlay on two new awards) and long tenors exposing to funding shifts.

7 total filings
· daily

General Federal Contracts — March 25, 2026

Dominant $2.95B NASA obligation to Caltech (68% of total) confirms long-term space R&D stability but neutral equity impact as nonprofit. Bullish signals across $1.13B in health/pharma/IT (Elevance $505M, Emergent $422M) and security/IT (Elbit $105M, Pyramid $100M) highlight reliable fed revenue through 2026-2030. HHS contracts total $1.19B (28%), signaling healthcare services momentum amid $4.34B overall obligations with 4 bullish, 3 neutral signals.

7 total filings
· daily

All NASA Contracts — March 25, 2026

NASA's $2.95B obligation to Caltech for JPL operations (with $2.43B outlayed and $3.15B potential including options) through 2028 confirms stable, non-competitive funding for space R&D including Europa Clipper, but as a nonprofit FFRDC, offers no direct equity exposure. This sole contract in the period highlights concentrated reliance on JPL for critical missions amid a 10-year term. Investors should monitor task order issuances and option exercises for indirect sector signals.

1 total filings
· daily

S&P 500 Technology Sector SEC Filings — March 25, 2026

Across 25 filings in the USA S&P 500 Technology intelligence stream (despite sector mix including non-tech), proxy statements dominate (12/25) signaling AGM season kickoff with May 2026 meetings, emphasizing governance enhancements like board refreshment at Century Communities and Cadence. Financial results show mixed trends: revenue growth in standouts like Adobe (+12% YoY to $6.4B subscription-driven) and Lafayette Square (+50% investment income to $84.7M), contrasted by declines in Dyadic (-12% YoY revenue) and Planet 13 (-11.2% FY revenue). Capital returns remain robust with $144M buybacks at Century Communities, $2.5B repurchases at Adobe, and $0.25 quarterly dividend at Dime Community. Leadership transitions emerge as a theme in tech-relevant names: Adobe CEO Shantanu Narayen stepping down (search underway), TXN SVP retirement, and Muzinich funds' C-suite overhaul. Period-over-period, 4/7 key financial filers posted YoY revenue growth (avg +17%), but margins mixed with Planet 13 improving to 38.6% yet EBITDA flipping to loss; non-tech outliers like Century Communities highlight operational efficiencies (costs -13k/home). Tech sector implications: Adobe's strength and Micron's debt tender signal balance sheet optimization amid AI/semiconductor cycles, positioning for H2 catalysts.

13 high priority 12 medium 25 total filings
· daily

Nasdaq 100 Stocks SEC Filings — March 25, 2026

Across 20 NASDAQ-100 related SEC filings from March 25, 2026, key themes include robust capital returns via dividends and buybacks (e.g., Century Communities $178.4M dividends + $144M repurchases, Adobe $2.48B buybacks), mixed financial performance with standout growth in homebuilding (Century rev $4.1B) and software (Adobe +12% YoY rev to $6.4B) offset by biotech declines (Dyadic -12% rev, wider losses) and banking stress (TCBS NPAs +316% to 2.65%). Leadership transitions dominate tech and funds (Adobe CEO search, TXN SVP retirement, Muzinich dual entities CEO/CFO changes effective Apr 1), signaling potential continuity risks but no disagreements noted. Period-over-period trends show YoY revenue growth averaging +7% in highlighted firms (Adobe +12%, Century strong units), but asset/loan quality deterioration in banks (TCBS assets -3% YoY, deposits -2%). Capital allocation leans shareholder-friendly with steady dividends (Dime $0.25, CMC $0.20), while debt actions (Micron tenders, OneMeta $2.2M notes maturing Mar 26) and SPAC stasis (Axiom no combo) add liquidity nuances. Portfolio implications favor overweighting growth outperformers like Adobe/Century amid sector rotation from stressed small caps.

11 high priority 9 medium 20 total filings
· daily

S&P 500 Financials Sector SEC Filings — March 25, 2026

Across 50 SEC filings from S&P 500 Financials and related entities dated March 25, 2026, overarching themes include resilient revenue growth in select tech-adjacent financial services (avg 16% YoY in Pure Storage, UiPath, Braze) offset by margin compression (avg -100bps in Rentokil, Braze, Spectral AI) and persistent SPAC challenges with high redemptions eroding trust balances (e.g., Concord -99.6%, byNordic -53%). Capital allocation leans shareholder-friendly with dividend hikes (Zedge +25% to $0.02/share), buybacks (News Corp $1B program, Chiba Bank ¥14.5B preferred repurchase), and M&A activity (Sandisk $1B Nanya stake at 15% discount, Thermon/CECO merger synergies). Mixed sentiment prevails (28/50 mixed/neutral), with positive signals from profitability turnarounds (UiPath $282M net income vs prior loss) and forward catalysts like AGMs (NOVAGOLD May 14), liquidations (Stratus $29.73-$37.69/share), and Phase 2 trials (Maze Therapeutics mid-2026). Portfolio-level trends show 12/20 revenue reporters growing >10% YoY but 8/15 loss-makers widening deficits amid high opEx (avg +20% in Pure, Braze). Key implications: Favor growth names with cash buffers (Chewy $860M cash, Energous $39.4M post-raise) over liquidity-strapped SPACs; monitor Q2 catalysts for alpha.

31 high priority 19 medium 50 total filings
· daily

S&P 500 Consumer Staples Sector SEC Filings — March 25, 2026

Across 50 filings in the USA S&P 500 Consumer Staples intelligence stream (broadly encompassing food, beverages, household, and related sectors amid mixed filings), overarching themes include modest revenue growth in select REITs and producers (avg +1-15% YoY in AFFO/revenues for Modiv/Global Self/Fresh Del Monte), robust M&A activity (e.g., Fresh Del Monte's $285M Del Monte assets acquisition), stable dividend declarations (Armour $0.24/share, Global Self $0.0725/qtr), and neutral compliance-heavy trust/SPAC reports dominating volume. Period-over-period trends show mixed results: AFFO/FFO growth (Modiv +15.1% YoY, Global Self +3.4%) offset by net income declines (Modiv -91.5%, Global Self -4%) and impairments, with Consumer Staples standouts like Fresh Del Monte and Hershey showing expansion via deals/proxies. Critical developments include positive merger synergies (Thermon/CECO), FDA priority review (Celcuity PDUFA Jul 17, 2026), and NYSE delisting risks (SelectQuote), implying sector resilience in branded foods amid macro pressures but vigilance on REIT-like exposures misaligned with staples. Portfolio-level patterns reveal 4/10 key filings with YoY revenue/NOI stability (+0.6-1.4%), dividend commitment signaling conviction, and upcoming catalysts in meetings/M&A closings driving near-term alpha.

30 high priority 20 medium 50 total filings
· daily

S&P 500 Industrials Sector SEC Filings — March 25, 2026

Across the 50 filings in the USA S&P 500 Industrials intelligence stream (broadly encompassing aerospace, defense, machinery, transportation, construction, and adjacent sectors), sentiment is mixed with 14 positive, 16 mixed, and 20 neutral/bearish outcomes, highlighting revenue resilience in select industrials (Winnebago +6% QoQ, Generac $4.2B FY sales) amid broader challenges in adjacent biotech/pharma and financials. Key period-over-period trends include revenue growth averaging +12% YoY in growth outperformers (Pure Storage +16%, Local Bounti +27%, ECB Bancorp NII +29%), but persistent net losses in biotech (Kiora -$10.8M vs +$3.6M prior, Armata -$173M), margin pressures (Pure Storage opex +17-20%), and asset quality deterioration (Texas Community NPA +316%). Critical developments feature M&A momentum (Fresh Del Monte $285M acquisition, Merck/Terns $6.7B at 31% premium), dividend hikes signaling confidence (Zedge +25% to $0.02, Parke $0.18), and SPAC trust balances exceeding $230M (Aldel $243M, Range $232M). Capital allocation favors returns (3M $4.8B dividends/buybacks, Armour $0.24 monthly div), with forward catalysts clustered in May 2026 proxy meetings and Q2-Q3 pharma readouts. Portfolio-level patterns show industrials/transport outperforming (e.g., Winnebago profitable turnaround) versus biotech drags, implying selective rotation into revenue growers with strong balance sheets.

32 high priority 18 medium 50 total filings